Ultraviolet Germicidal Irradiation Global Market Report 2022-2026

Efficiency and Improved ROI Make UV-C Disinfection Technology an Ideal Option for Hospitality Industry

The “Ultraviolet Germicidal Irradiation (UVGI) – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Ultraviolet Germicidal Irradiation estimated at US$454.4 Million in the year 2022, is projected to reach a revised size of US$682.9 Million by 2026, growing at a CAGR of 12% over the analysis period. Air Disinfectant, one of the segments analyzed in the report, is projected to grow at a 12.3% CAGR to reach US$646.1 Million by the end of the analysis period.

The COVID-19 crisis is fostering the ultraviolet (UV) disinfection equipment market by creating a pressing need to effectively deal with the deadly virus. UV disinfection represents a chemical-free process that exposes pathogens in a gaseous or liquid medium or on surfaces to UV irradiation for deactivating the DNA to hinder reproduction of the pathogen.

Several studies have indicated that the use of a specific wavelength of UV light can kill over 99.9% of COVID-19 viruses present on surfaces and in airborne droplets. In addition, UVC germicidal irradiation offers effective physical disinfection as well as holds optimal germicidal effect and doesn`t leave any residues.

These benefits have resulted in strong demand and adoption of UV disinfection equipment across healthcare settings, offices and other work spaces. The COVID-19 outbreak provided a significant impetus to global shipment of UV disinfection equipment, a trend that is unlikely to abate soon.

 After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Surface Disinfectant segment is readjusted to a revised 10.3% CAGR for the next 7-year period. This segment currently accounts for a 14.2% share of the global Ultraviolet Germicidal Irradiation market.

The U.S. Market is Estimated at $149.1 Million in 2022, While China is Forecast to Reach $73.7 Million by 2026

The Ultraviolet Germicidal Irradiation market in the U.S. is estimated at US$149.1 Million in the year 2022. The country currently accounts for a 33.51% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$73.7 Million in the year 2026 trailing a CAGR of 15% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 10.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.8% CAGR while Rest of European market (as defined in the study) will reach US$81.2 Million by the close of the analysis period.

Key Players

  • American Ultraviolet
  • Atlantic Ultraviolet Corporation
  • Ensavior
  • Excelitas Technologies Corp.
  • General Electric Company
  • Halma plc
  • Signify Holding
  • UltraViolet Devices, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Upper-Room UVGI: A Useful Ventilation Solution to Combat COVID-19
  • Rising Incidence of Hospital Acquired Infections Propel Demand
  • Focus on HAI Prevention Practices Drives Demand
  • High Touch Surfaces: The Major Causative Factor in HAIs
  • Renewed Threat of Infectious Diseases to Drive Adoption
  • Ultraviolet Germicidal Irradiation for Commercial Settings
  • Mobile UV Systems and Handheld UV Sanitizers Come to the Fore
  • Trend towards Preventive Healthcare Benefits Disinfectants Market
  • Market Witnesses Influx of New UV Disinfection Robots
  • The Way Forward
  • Mitigating COVID-19 Transmission Risk in Hospitals Gets Interesting at UV Disinfection Robot Levels
  • Lucrative Prospects in the Airports Vertical
  • Efficiency and Improved ROI Make UV-C Disinfection Technology an Ideal Option for Hospitality Industry
  • Benefits of UV-C Disinfection for Hospitality and Lodging Industry
  • Restaurants Bet on UV Germicidal Irradiation for Safer Environments
  • Robust Opportunities in Cinema Halls & Shopping Malls
  • Stringent Regulations Regarding Food Safety to Augment Deployment of UV Disinfection
  • Food Sterilization Applications for UVC Germicidal Lamps
  • Cold Storage and Refrigerated Spaces for Fruits and Vegetables Augment Demand

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version